Boundless Bio, Inc.
BOLDNASDAQHealthcare● Active
$1.43
+$0.01(+0.70%)
Market Cap$32123679
P/E Ratio—
52W High$1.68
52W Low$0.961
Boundless Bio, Inc. (BOLD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BOLD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.60
Est. -$0.51 · -17.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS
BOLD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.60 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.51 | -$0.60 | -17.6% | — | — | — |
| ▼ Q1 FY2026 | Mar 9, 2026 | -$0.44 | -$0.58 | -31.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$0.53 | -$0.62 | -17.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.75 | -$0.70 | +6.7% | — | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.68 | -$0.71 | -4.4% | — | — | — |
| — Q1 FY2025 | Mar 27, 2025 | -$0.74 | -$0.74 | +0.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.76 | -$0.74 | +2.6% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.60
EPS Est.
-$0.51
EPS Surpr.
-17.6%
Revenue
—
Q1 FY2026
Mar 9, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.44
EPS Surpr.
-31.8%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.53
EPS Surpr.
-17.0%
Revenue
—
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.70
EPS Est.
-$0.75
EPS Surpr.
+6.7%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.71
EPS Est.
-$0.68
EPS Surpr.
-4.4%
Revenue
—
Q1 FY2025
Mar 27, 2025
EPS Actual
-$0.74
EPS Est.
-$0.74
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.74
EPS Est.
-$0.76
EPS Surpr.
+2.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q2 FY2027 | $-0.70 | $-0.70 | $-0.70 | 1 |
| Q1 FY2027 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q4 FY2026 | $-0.57 | $-0.57 | $-0.57 | 1 |
| Q3 FY2026 | $-0.63 | $-0.63 | $-0.63 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -17.6% | $1.53 | $1.44 | -5.88% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -31.8% | $1.13 | $1.14 | +0.88% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -17.0% | $1.30 | $1.26 | -3.08% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +6.7% | $1.20 | $1.18 | -1.67% |
| ▼ Q2 FY2025 | May 9, 2025 | -4.4% | $1.50 | $1.44 | -4.00% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +0.0% | $1.52 | $1.51 | -0.66% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +2.6% | $3.17 | $3.32 | +4.73% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +1.3% | $3.07 | $2.88 | -6.19% |
Q2 FY2026-5.88%
Report Date
May 8, 2026
EPS Beat/Miss
-17.6%
Price Before
$1.53
Price After
$1.44
Q1 FY2026+0.88%
Report Date
Mar 9, 2026
EPS Beat/Miss
-31.8%
Price Before
$1.13
Price After
$1.14
Q4 FY2025-3.08%
Report Date
Nov 5, 2025
EPS Beat/Miss
-17.0%
Price Before
$1.30
Price After
$1.26
Q3 FY2025-1.67%
Report Date
Aug 5, 2025
EPS Beat/Miss
+6.7%
Price Before
$1.20
Price After
$1.18
Q2 FY2025-4.00%
Report Date
May 9, 2025
EPS Beat/Miss
-4.4%
Price Before
$1.50
Price After
$1.44
Q1 FY2025-0.66%
Report Date
Mar 27, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.52
Price After
$1.51
Q4 FY2024+4.73%
Report Date
Nov 7, 2024
EPS Beat/Miss
+2.6%
Price Before
$3.17
Price After
$3.32
Q3 FY2024-6.19%
Report Date
Aug 12, 2024
EPS Beat/Miss
+1.3%
Price Before
$3.07
Price After
$2.88
Avg Beat Reaction-0.95%
Avg Miss Reaction-3.02%
Beat Rate4 / 8 quarters
Largest Move-6.19% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BOLD ends December
Boundless Bio, Inc. (BOLD) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.60 — missing the analyst consensus of $-0.51 by -17.6%. The next BOLD earnings date is expected around September 1, 2026.
Each quarter, investors track BOLD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BOLD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BOLD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BOLD earnings · 5 questionsBoundless Bio, Inc.'s next earnings report is expected around September 1, 2026. BOLD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BOLD historically reports after market close (AMC).
BOLD earnings datewhen is BOLD earningsBOLD next earnings datewhen does BOLD report earningsBOLD earnings calendar
▸ Source: FMP · Boundless Bio, Inc. SEC filings · US GAAP · Boundless Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026